ATE330632T1 - Selektion von fxr-rezeptormodulatoren - Google Patents

Selektion von fxr-rezeptormodulatoren

Info

Publication number
ATE330632T1
ATE330632T1 AT04075173T AT04075173T ATE330632T1 AT E330632 T1 ATE330632 T1 AT E330632T1 AT 04075173 T AT04075173 T AT 04075173T AT 04075173 T AT04075173 T AT 04075173T AT E330632 T1 ATE330632 T1 AT E330632T1
Authority
AT
Austria
Prior art keywords
fxr
selection
receptor modulators
methods
fxr receptor
Prior art date
Application number
AT04075173T
Other languages
English (en)
Inventor
Barry M Forman
Haibo Wang
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE330632T1 publication Critical patent/ATE330632T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
AT04075173T 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren ATE330632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12633499P 1999-03-26 1999-03-26

Publications (1)

Publication Number Publication Date
ATE330632T1 true ATE330632T1 (de) 2006-07-15

Family

ID=22424256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075173T ATE330632T1 (de) 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren
AT00918345T ATE274921T1 (de) 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00918345T ATE274921T1 (de) 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren

Country Status (7)

Country Link
EP (1) EP1165135B1 (de)
JP (1) JP2004510682A (de)
AT (2) ATE330632T1 (de)
AU (1) AU780658B2 (de)
CA (1) CA2368234A1 (de)
DE (2) DE60029029T2 (de)
WO (1) WO2000057915A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140079B1 (de) 1998-12-23 2009-06-03 Glaxo Group Limited Bestimmungsmethode fur liganden der nuklearen rezeptoren
AU2002213893A1 (en) * 2000-09-16 2002-03-26 Lion Bioscience Ag Nuclear receptor l66 and methods of use
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
AU2002367060A1 (en) 2001-12-21 2003-07-30 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
US7781175B2 (en) * 2004-04-23 2010-08-24 Takeda Pharmaceutical Company Limited Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
PL2376519T3 (pl) 2008-11-19 2014-04-30 Intercept Pharmaceuticals Inc Modulatory TGR5 i sposoby ich zastosowania
PT2435410T (pt) 2009-05-28 2017-05-03 Bristol Myers Squibb Co Resumo
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
RU2658013C2 (ru) 2011-09-19 2018-06-19 Этх Цюрих Модуляторы ror-гамма
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
AU2013277429B2 (en) 2012-06-19 2016-01-14 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
US11208664B2 (en) 2016-09-12 2021-12-28 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6516094A (en) * 1993-02-05 1994-08-29 Board Of Regents, The University Of Texas System Cholesterol 7-alpha hydroxylase expression regulation
EA199800279A1 (ru) * 1995-10-11 1999-04-29 Талариа Терапьютикс, Инк Липосомные композиции и способы их применения
WO1997035195A1 (en) * 1996-03-19 1997-09-25 The Salk Institute For Biological Studies In vitro methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
DE69731084T2 (de) * 1996-03-20 2006-02-23 Dyax Corp., Cambridge REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA)

Also Published As

Publication number Publication date
AU3917300A (en) 2000-10-16
DE60013417T2 (de) 2005-09-15
AU780658B2 (en) 2005-04-07
EP1165135A1 (de) 2002-01-02
CA2368234A1 (en) 2000-10-05
WO2000057915A1 (en) 2000-10-05
DE60013417D1 (de) 2004-10-07
DE60029029T2 (de) 2007-06-14
EP1165135B1 (de) 2004-09-01
JP2004510682A (ja) 2004-04-08
DE60029029D1 (de) 2006-08-03
ATE274921T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
ATE330632T1 (de) Selektion von fxr-rezeptormodulatoren
WO2003030612A3 (en) Methods for modulating activity of the fxr nuclear receptor
EP1073465A4 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
NO20070898L (no) Diversitetsinnfelling av kodebiter ved plassering og blanding
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
NO980198D0 (no) Modulatorer av funksjonen til FAS-reseptorer og andre proteiner
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
DK1200831T3 (da) Modulatorisk bindingssted i kaliumkanaler til screening
IL124652A (en) Screening assay for compounds stimulating somatostatin and insulin production
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
ATE321887T1 (de) Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
WO2002099438A3 (en) Modulation of steroid hormone uptake
TW200634155A (en) Polynucleotides of DHS and isoforms of EIF-5A and methods of using same
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator
ATE389727T1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties